XML 26 R77.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Related Party Transactions - Additional Information (Details) (USD $) | 3 Months Ended | 1 Months Ended | 33 Months Ended | 0 Months Ended |
--- | --- | --- | --- | --- | ---
Mar. 31, 2015 | Mar. 31, 2014 | Mar. 31, 2015 | Feb. 28, 2015 | Oct. 31, 2013 | Dec. 07, 2014 | Sep. 30, 2013 | Nov. 20, 2013 | Sep. 30, 2014 | Dec. 31, 2014
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Compensation expense | $ 0 xon_ContributionOfServicesByShareholder | $ 470,000 xon_ContributionOfServicesByShareholder |  |  |  |  |  |  |  |
Payments to acquire other investments | 14,900,000 us-gaap_PaymentsToAcquireOtherInvestments | 0 us-gaap_PaymentsToAcquireOtherInvestments |  |  |  |  |  |  |  |
Assets, Fair Value Disclosure | 387,188,000 us-gaap_AssetsFairValueDisclosure |  | 387,188,000 us-gaap_AssetsFairValueDisclosure |  |  |  |  |  |  | 280,497,000 us-gaap_AssetsFairValueDisclosure
Collaboration revenue | 14,735,000 xon_CollaborationRevenues | 7,837,000 xon_CollaborationRevenues |  |  |  |  |  |  |  |
Third Security |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Total amount of expenses reimbursed | 41,000 us-gaap_ProfessionalAndContractServicesExpense / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ThirdSecurityMember | 24,000 us-gaap_ProfessionalAndContractServicesExpense / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ThirdSecurityMember |  |  |  |  |  |  |  |
Chief Executive Officer |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Compensation expense |  | 470,000 xon_ContributionOfServicesByShareholder / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = us-gaap_ChiefExecutiveOfficerMember |  |  |  |  |  |  |  |
AmpliPhi Biosciences Corp |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Shares of common stock purchased from collaborative partners |  |  | 13,939,392 xon_SharesPurchasedFromCollaborativePartners / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember |  |  |  |  |  |  |
Warrants purchased from collaborative partners |  |  | 3,484,848 xon_WarrantsPurchasedFromCollaborativePartners / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember |  |  |  |  |  |  |
Payments to acquire other investments |  |  | 2,300,000 us-gaap_PaymentsToAcquireOtherInvestments / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember |  |  |  |  |  |  |
ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Common stock purchase commitment | 50,000,000 xon_AdditionalSharesValueAgreedToPurchase / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ZiopharmMember |  | 50,000,000 xon_AdditionalSharesValueAgreedToPurchase / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ZiopharmMember |  |  |  |  |  |  |
Shares of common stock purchased from collaborative partners |  |  |  | 12,600,000 xon_SharesPurchasedFromCollaborativePartnersValue / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ZiopharmMember | 30,982,000 xon_SharesPurchasedFromCollaborativePartnersValue / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ZiopharmMember |  |  |  |  |
Histogenics Corporation |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Shares of common stock purchased from collaborative partners |  |  |  |  |  | 1,772,364 xon_SharesPurchasedFromCollaborativePartners / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_HistogenicsCorporationMember |  |  |  |
Note receivable, stated interest rate |  |  |  |  |  |  |  |  | 6.00%xon_NoteReceivableInterestRate / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_HistogenicsCorporationMember |
Price per share of common shares |  |  |  |  |  | $ 11.00 xon_SharesPurchasedPricePerShare / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_HistogenicsCorporationMember |  |  |  |
Oragenics, Inc. |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Shares of common stock purchased from collaborative partners |  |  |  |  |  |  | 1,300,000 xon_SharesPurchasedFromCollaborativePartners / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember |  |  |
Price per share of common shares |  |  |  |  |  |  |  |  | $ 3.00 xon_SharesPurchasedPricePerShare / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember |
Maximum percentage of shares of future securities offerings of collaborative partners to which the entity is entitled to purchase | 30.00%xon_MaximumPercentageOfSharesEntitledToPurchase / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember |  | 30.00%xon_MaximumPercentageOfSharesEntitledToPurchase / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember |  |  |  |  |  |  |
Oragenics, Inc. | Share Purchase Rights Plan |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Shares of common stock purchased from collaborative partners |  |  |  |  |  |  |  | 1,100,000 xon_SharesPurchasedFromCollaborativePartners / invest_InvestmentAxis = xon_SharePurchaseRightsPlanMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember |  |
Price per share of common shares |  |  |  |  |  |  |  | $ 2.50 xon_SharesPurchasedPricePerShare / invest_InvestmentAxis = xon_SharePurchaseRightsPlanMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember |  |
Related Parties, Aggregated |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 12,796,000 xon_CollaborationRevenues / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_RelatedPartiesAggregatedMember | 7,398,000 xon_CollaborationRevenues / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_RelatedPartiesAggregatedMember |  |  |  |  |  |  |  |
Common Stock | AmpliPhi Biosciences Corp |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Payments to acquire other investments |  |  | 1,979,000 us-gaap_PaymentsToAcquireOtherInvestments / us-gaap_InvestmentTypeAxis = us-gaap_CommonStockMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember |  |  |  |  |  |  |
Warrants | AmpliPhi Biosciences Corp |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Payments to acquire other investments |  |  | 321,000 us-gaap_PaymentsToAcquireOtherInvestments / us-gaap_InvestmentTypeAxis = us-gaap_WarrantMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember |  |  |  |  |  |  |
Assets, Fair Value Disclosure | 756,000 us-gaap_AssetsFairValueDisclosure / us-gaap_InvestmentTypeAxis = us-gaap_WarrantMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember |  | 756,000 us-gaap_AssetsFairValueDisclosure / us-gaap_InvestmentTypeAxis = us-gaap_WarrantMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember |  |  |  |  |  |  |
Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 3,031,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember | 1,882,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember |  |  |  |  |  |  |  |
Upfront and Milestone Payments | Upfront | Histogenics Corporation |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, value of convertible promissory note |  |  |  |  |  |  |  |  | $ 10,000,000 xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_HistogenicsCorporationMember |

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with other investments held by the entity for investment purposes not otherwise defined in the taxonomy. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support. + References No definition available. + Details
Name: | us-gaap_ProfessionalAndContractServicesExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of additional common stock for which the entity has committed to purchasing from collaborator, original + References No definition available. + Details
Name: | xon_AdditionalSharesValueAgreedToPurchase
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration agreements. + References No definition available. + Details
Name: | xon_CollaborationRevenues
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Compensation expense recognized for value of services contributed by a shareholder + References No definition available. + Details
Name: | xon_ContributionOfServicesByShareholder
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of shares that the entity is entitled to purchase in securities offerings conducted by collaborator, maximum. + References No definition available. + Details
Name: | xon_MaximumPercentageOfSharesEntitledToPurchase
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Interest rate per annum of the note receivable. + References No definition available. + Details
Name: | xon_NoteReceivableInterestRate
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares of common stock purchased from collaborator + References No definition available. + Details
Name: | xon_SharesPurchasedFromCollaborativePartners
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of common stock purchased from collaborator + References No definition available. + Details
Name: | xon_SharesPurchasedFromCollaborativePartnersValue
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price per share of collaborator's common stock purchased + References No definition available. + Details
Name: | xon_SharesPurchasedPricePerShare
Namespace Prefix: | xon_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of warrants purchased from collaborator + References No definition available. + Details
Name: | xon_WarrantsPurchasedFromCollaborativePartners
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_AmpliPhiBiosciencesCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_HistogenicsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_OragenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_RelatedPartiesAggregatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_ThirdSecurityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |